Fortune Smiles 88
liked and commented on
$Esperion Therapeutics (ESPR.US)$Esperion initiated with an Overweight at Cantor Fitzgerald - TipRanks.com BELOW is a Detailed research report that should convince readers to have a portion of their investment portfolio in Esperion. This is not a pump article, please take the time to read and fact check. This $2 stock will be $20+ by 2027. Esperion anticipates Billions in Revenues.
Es...
Es...
15
1
Fortune Smiles 88
commented on
Fortune Smiles 88
commented on
Fortune Smiles 88
liked
2
Fortune Smiles 88
liked and commented on
Fortune Smiles 88
commented on
$Esperion Therapeutics (ESPR.US)$ Game over
Translated
1
6
Fortune Smiles 88
commented on
Anyone praying for green today?
1
9
Fortune Smiles 88 : I agree. Low risk high gain opportunity. Retail price for one month nexletol/nexlizer cost $400 per patient. Assuming just 1m patients in USA alone, will net Esperian gross sales of $400m a months or close to half a billion annually. Extrapolate it to global population. Potential is immense.